Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
8737150 | Current Opinion in Immunology | 2016 | 7 Pages |
Abstract
B cells have emerged as effective targets for therapeutic intervention in autoimmunities in which the ultimate effectors are antibodies, as well as those in which T cells are primary drivers of inflammation. Proof of this principle has come primarily from studies of the efficacy of Rituximab, an anti-CD20 mAb that depletes B cells, in various autoimmune settings. These successes have inspired efforts to develop more effective anti-CD20s tailored for specific needs, as well as biologicals and small molecules that suppress B cell function without the risks inherent in B cell depletion. Here we review the current status of B cell-targeted therapies for autoimmunity.
Related Topics
Life Sciences
Immunology and Microbiology
Immunology
Authors
S Elizabeth Franks, Andrew Getahun, P Mark Hogarth, John C Cambier,